when does semaglutide go off patent The upcoming expiry of the in India in mid-March 2026 is expected to transform the country's diabetes treatment landscape. Ahead of this, industry experts predict that the development will open Looming GLP-1 drug patent expirations

If you have obesity or are overweight, youre more likely to get insurance coverage for weight loss medications if you have a weight-related health condition, such as Type 2 diabetes, cardiovascular disease, or obstructive sleep apnea

This unique mechanism of action distinguishes it from other weight loss medications and has yielded promising results in clinical studies

Nearly 75% of those are older than 45

6 Alternatively, some patients may be prescribed sulfonylureas or thiazolidiniones to improve insulin secretion, but both of these treatment options are associated with an elevated risk of heart failure making them unsuitable for use in patients with cardiovascular disease

During regular check-in appointments, we'll look at how well the treatment is working for you, chat about any questions or worries you might have, and tweak your losing weight strategy as needed to keep you on the path to your goals

Zepbound (Tirzepatide) Zepbound uses a dual-agonist approach, affecting both GLP-1 and GIP hormones for enhanced weight loss